Effects of Low Lactose Milk Containing GOS on Digestive Response in Healthy Chinese Adults
NCT ID: NCT06598124
Last Updated: 2025-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2024-08-20
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Galacto-Oligosaccharides on Adult Microbiome
NCT05207839
The Effect of Galactooligosaccharides (GOS) on the Gut Microbiota of Lactose Intolerance Individuals
NCT06915129
Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls
NCT01263847
Effect of Probiotic Supplementation on Lactose Maldigestion Induced by Fat-free Milk
NCT03659747
Safety, Tolerability, and Biosignature of Humanized Prebiotics in Healthy Adults
NCT06068894
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
24 healthy participants of Chinese ethnicity are planned to be enrolled. Participants will be invited to three visit days at the research site: a screening visit and two test days, 3 to 28 days apart.
During the test days, participants will be requested, after overnight fasting, to consume either the investigational product (IP), a skimmed milk powder with low lactose content and GOS, or the comparator product (CP) a matching skimmed milk powder, both reconstituted in water. Participants will then undergo a series of tests to compare the effects of these two drinks on gastrointestinal fluid retention and motility as well as on gut comfort.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Visit 1: Comparator Product; Visit 2: Investigational Product
Investigational Product (IP)
1 single dose of IP consisting in 400 mL of milk with low lactose content and GOS.
Comparator Product (CP)
1 single dose of CP consisting in 400 mL of milk with lactose
Arm 2
Visit 1: Investigational Product; Visit 2: Comparator Product
Investigational Product (IP)
1 single dose of IP consisting in 400 mL of milk with low lactose content and GOS.
Comparator Product (CP)
1 single dose of CP consisting in 400 mL of milk with lactose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Investigational Product (IP)
1 single dose of IP consisting in 400 mL of milk with low lactose content and GOS.
Comparator Product (CP)
1 single dose of CP consisting in 400 mL of milk with lactose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Women and men aged between 18 and 60 years
3. Body mass index (BMI ≥ 18.5 \& \<30 kg/m2)
4. Healthy: no medical conditions or previous gastrointestinal surgery which might affect study measurements (as declared by the participant)
5. Able to understand and to sign written informed consent prior to study entry
6. Informed consent signed
7. Meets all the criteria for MRI Scan
8. Can read and speak English
Exclusion Criteria
2. Subjects not willing and/or not able to comply with scheduled visits and the requirements of the study protocol
3. Diagnosed with any gastrointestinal disorders
4. History of claustrophobia
5. Pregnant (defined by pregnancy test) or breast feeding
6. History or current psychiatric illness
7. History or current neurological condition (e.g. epilepsy)
8. Consumption of \> 21 alcoholic drinks in a typical week (one serving is 0.4 dl of spirits, 1 dl of wine, or 3 dl of beer as declared by participant)
9. Currently smoking (as declared by participant)
10. Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance
11. Antibiotic use within the 4 weeks preceding the intervention
12. Probiotic \& prebiotics use within the 2 weeks preceding the intervention
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Nottingham
OTHER
Société des Produits Nestlé (SPN)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Irma Silva Zolezzi
Role: STUDY_DIRECTOR
Societé des Produits Nestlé SA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Nottingham
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2314NR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.